Lee Rodne, CEO of LTR Pharma, Discusses His Company's New Nasal Spray Formulation for ED
HTML-код
- Опубликовано: 7 сен 2024
- LTR's new drug, Spontan, is a “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of ED. The company is nearing commercialization and just completed a successful capital raise that will propel the drug into Australian and US markets in the near future.
Here is my write-up on LTR Pharma simonschase.co... This is not investment advice. Do not rely on the contents of this video. Do your own due diligence.
Great interview Simons.
This looks fantastic. Great informative video. I am looking forward to seeing this in the market soon.
What is to stop competitors copying the product? What are the details of the supply agreement with maker of drug in Spontan, is it exclusive supply agreement?
1. Patents filed gives the company protection
2. Vardenafil a generic drug produced by numerous suppliers so supply is not an issue